PKM2 Inhibitor Shikonin Overcomes the Cisplatin Resistance in Bladder Cancer by Inducing Necroptosis

Cisplatin-based chemotherapy often results in the development of chemo-resistance when used to treat bladder cancer (BC), which is difficult to overcome. Recent data indicate that pyruvate kinase M2 (PKM2), a glycolytic enzyme for Warburg effect, is strongly upregulated in BC, and contributes to the...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yonggang, Hao, Fangshi, Nan, Yonghao, Qu, Licheng, Na, Wanli, Jia, Chunshu, Chen, Xiaoliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6231221/
https://www.ncbi.nlm.nih.gov/pubmed/30443191
http://dx.doi.org/10.7150/ijbs.27854

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6231221/
https://www.ncbi.nlm.nih.gov/pubmed/30443191
http://dx.doi.org/10.7150/ijbs.27854

Ejemplares similares